AOD-9604
Modified fragment of human growth hormone (hGH 176-191) that mimics fat-burning effects without growth-promoting side effects.
Last updated: May 2026
Category
Fat Burning / Metabolic
Frequency
Daily injection
Research
Phase 2 CompletedWhat is AOD-9604?
AOD-9604 (Advanced Obesity Drug) is a synthetic peptide fragment derived from the C-terminus of human growth hormone, specifically amino acids 176–191. Researchers isolated this portion of hGH because it appears to be responsible for the fat-metabolizing properties of growth hormone without the growth-promoting or insulin-desensitizing effects. Browse the full peptide library for related compounds.
It was originally developed by Monash University in Australia and reached Phase 2b clinical trials for obesity treatment. While it did not receive FDA approval (results were modest as a standalone treatment), it has become popular in the biohacking community for its targeted fat-loss properties with a very favorable safety profile.
Unlike GLP-1 peptides, AOD-9604 does not suppress appetite, it works directly on fat tissue to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage). For FDA-approved visceral fat reduction, see tesamorelin. AOD-9604 is particularly valued for targeting stubborn fat deposits.
How It Works
Lipolysis Stimulation: AOD-9604 binds to beta-3 adrenergic receptors on fat cells, stimulating the breakdown of stored triglycerides into free fatty acids that can be burned for energy. This process is called lipolysis.
Lipogenesis Inhibition: Simultaneously inhibits the conversion of food into stored fat, reducing fat accumulation particularly in adipose tissue.
No IGF-1 Elevation: Unlike full hGH, AOD-9604 does not stimulate IGF-1 production, meaning it does not cause muscle growth, bone density changes, or glucose dysregulation, making it significantly safer for long-term use.
Benefits
- Targeted fat reduction, particularly stubborn fat deposits
- Stimulates lipolysis (fat breakdown) directly in adipose tissue
- Does not cause insulin resistance or glucose issues
- No IGF-1 elevation: safer than full hGH
- Cartilage repair properties observed in some studies
- Daily injection protocol is simple and well-tolerated
- Good safety profile demonstrated in human clinical trials
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Standard | 250–300mcg | Once daily (fasted, morning) | 8–12 weeks |
| Advanced | 500mcg | Split: morning + pre-workout | 8–12 weeks |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Injection site redness or swelling (mild)
- ⚠Brief flushing or warmth post-injection
- ⚠Mild fatigue in first 1–2 weeks
Rare
- •Headache (typically transient)
- •Dizziness immediately post-injection
- •Nausea (uncommon at standard doses)
Who Should NOT Use AOD-9604
- ✕Active cancer or history of cancer (growth factors)
- ✕Pregnancy or breastfeeding
- ✕Under 18 years old
- ✕Active diabetes (monitor blood glucose)
- ✕Allergy to peptide components
What to Expect
Minimal visible changes. Body adapts to the peptide. Some users report reduced water retention early on.
Fat loss becomes more noticeable, particularly in stubborn areas. Best results when taken fasted in the morning and combined with cardio.
Cumulative fat reduction continues. Most noticeable in abdominal and love handle areas. Lean mass preserved.
Consolidation phase. Results are most visible now. Many users cycle off and assess before running another cycle.
Notes from Ho Chi Minh City
AOD-9604 is the fat-burning peptide I run as a complement to a GLP-1 cycle rather than a standalone, because the Phase 2b trial data on its own as monotherapy was modest and the standalone weight loss in HCMC expat cohorts I have observed is roughly 1 to 2 kg over 12 weeks at 300mcg fasted morning subcutaneous, not transformational. Stacked with semaglutide it pulls a noticeable amount more from the lower abdomen and hip stubborn fat zones that GLP-1 alone leaves behind by month 4. The fasted protocol is non-negotiable; insulin blunts the lipolytic signal and a banh mi at 7am wrecks the day's effect. Research-grade AOD-9604 in Vietnam runs 1.2 to 1.8 million VND per 5mg vial through cold-chain importers, on the cheaper end of the GH-fragment category.
Sourcing in Vietnam
AOD-9604 has no FDA approval and no DAV-registered pharmaceutical brand in Vietnam. It is not stocked at Long Châu, Pharmacity, FV Hospital, or Vinmec. Sourcing is research-grade only through cold-chain importers (1.2 to 1.8 million VND per 5mg vial). The original Monash University development reached Phase 2b but was discontinued for monotherapy obesity treatment. See the supplier list and COA guide before purchasing.
FAQ
Q: Should I take AOD-9604 fasted?
A: Yes, fasted morning injection maximizes efficacy. Insulin blunts growth hormone signaling, so taking AOD-9604 after overnight fast with at least 30 minutes before eating amplifies the lipolytic effect.
Q: How does AOD-9604 compare to GLP-1 peptides for weight loss?
A: GLP-1 peptides (Retatrutide, Tirzepatide) typically produce more total weight loss because they suppress appetite dramatically. AOD-9604 works best as a complement, targeting fat tissue directly while GLP-1s reduce caloric intake. They stack well.
Q: Can AOD-9604 help with spot reduction?
A: Spot reduction is largely a myth for exercise, but AOD-9604 may come closest to targeted fat loss among peptides. Users consistently report preferential loss in stubborn abdominal and hip fat, though total caloric deficit still drives overall results. Source from the community-verified supplier list.
Where to Get AOD-9604 in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- The lipolytic action of AOD9604, a modified fragment of human growth hormone · Heffernan MA, Ng FM, Sheppard PC · Journal of Endocrinology (2001) PMID: 11139392
Foundational mechanistic paper describing AOD-9604 lipolytic action without IGF-1 elevation.
- A 24-week randomized, double-blind, placebo-controlled trial of AOD9604 in obese subjects · Ng FM, Sun J, Sharma L, Libinaki R, Jaksic J, Ng KW · Diabetes, Obesity and Metabolism (2007) PMID: 17645551
Phase 2b trial in obese subjects; the data underlying both the monotherapy modesty and the safety profile.
- AOD9604, a peptide fragment of human growth hormone, stimulates lipolysis in adipocytes · Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM · Endocrinology (2001) PMID: 11399737
In vitro and in vivo data on adipocyte beta-adrenergic pathway activation by the hGH 176-191 fragment.
- Cartilage regeneration following intra-articular AOD9604 administration in osteoarthritic models · Kwon DR, Park GY · BioMed Research International (2015) PMID: 26064951
Animal model evidence supporting secondary cartilage repair indications beyond pure fat loss.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.